Sort
48,018 grants matching “immunotherapy”
Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeuticnanoparticles for TB
$436,239Jessica L Reynolds · State University Of New York At Buffalo · R01 · FY2022 · AI
Clinical Core
$436,178Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2013 · CA
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
$436,145Todd E. Golde · University Of Florida · R01 · FY2017 · AG
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
$436,145Todd E. Golde · University Of Florida · R01 · FY2018 · AG
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
$436,145Todd E. Golde · University Of Florida · R01 · FY2016 · AG
Biology of Alpha Particle Immunotherapy
$436,088David A Scheinberg · Sloan-Kettering Inst Can Research · R01 · FY2009 · CA
Biology of Alpha Particle Immunotherapy
$436,088David A Scheinberg · Sloan-Kettering Inst Can Research · R01 · FY2010 · CA
Eastern Cooperative Oncology Group
$436,068Vanderbilt University · U10 · FY2004 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$436,037Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2020 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$436,037Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2021 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$436,026Lei Zheng · Johns Hopkins University · R01 · FY2018 · CA
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.
$435,992David Porter · University Of Pennsylvania · P01 · FY2017 · CA
Molecular Mechanisms Controlling KIR Genes in NK Cells
$435,969University Of Kentucky · R01 · FY2005 · AI
BCL11B activation as an approach for enhancing the efficacy of immunotherapy
$435,925Chintan Parekh · Children'S Hospital Of Los Angeles · R01 · FY2021 · AI
Blocking NK cell shedding of CD16a to increase cancer cell killing
$435,886Bruce K Walcheck · University Of Minnesota · R01 · FY2019 · CA
Biomarkers of Persistent TB Infection and TB Treatment Relapse
$435,831C Robert Horsburgh · Boston Medical Center · U19 · FY2014 · AI
Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer
$435,827Benjamin G. Neel · New York University School Of Medicine · R21 · FY2025 · CA
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
$435,761David G Denardo · Washington University · R01 · FY2022 · CA
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
$435,761David G Denardo · Washington University · R01 · FY2023 · CA
Molecular Mechanisms Controlling KIR Genes in NK Cells
$435,696Charles T. Lutz · University Of Kentucky · R01 · FY2006 · AI
Development of Antigen-specific B Cell Memory
$435,683Michael G. McHeyzer-Williams · Scripps Research Institute, The · R01 · FY2013 · AI
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
$435,660Joseph John Barchi · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
$435,633Todd E. Golde · University Of Florida · R01 · FY2014 · AG
LILRB modulates tumor microenvironment and promotes tumor progression
$435,587Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2018 · CA
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
$435,560Benjamin Aaron Alman · Duke University · R01 · FY2016 · CA